

Drug & Therapeutics Committee
NICE Drug Technology Appraisals ratified by D&TC since 2018

These medicines have a positive NICE Technology Appraisal and are listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines

D&TC date	NICE TA date	Drug name	Indication
January 2018	November 2017 (TA486)	Aflibercept (recombinant fusion protein)	For treating choroidal neovascularisation
January 2018	November 2017 (TA487)	Venetoclax (selective inhibitor of B-cell lymphoma-2 (BCL-2))	For treating chronic lymphocytic leukaemia
January 2018	November 2017 (TA488)	Regorafenib (inhibitor of several protein kinases)	For previously treated unresectable or metastatic gastrointestinal stromal tumours
January 2018	November 2017 (TA489)	Vismodegib (hedgehog pathway inhibitor)	For treating of adult patients with: symptomatic metastatic basal cell carcinoma; locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.
January 2018	November 2017 (TA490)	Nivolumab (human immunoglobulin G4 monoclonal antibody)	For treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
January 2018	November 2017 (TA491)	Ibrutinib (tyrosine kinase inhibitor)	For treating Waldenstrom's macroglobulinaemia
January 2018	December 2017 (TA492)	Atezolizumab (monoclonal antibody, which binds to the programmed death-1 (PD-1) receptor)	For untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

January 2018	December 2017 (TA493)	Cladribine (antimetabolite)	For treating relapsing–remitting multiple sclerosis
March 2018	December 2017 (TA 494)	Naltrexone – bupropion (Centrally acting appetite suppressants)	Adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (aged 18 and over) with an initial BMI of: <ul style="list-style-type: none"> • 30 kg/m² or more (obese) or • from 27 kg/m² to 30 kg/m² (overweight) in the presence of one or more weight-related co-morbidities (such as type 2 diabetes, dyslipidaemia, or controlled hypertension). Treatment should be stopped after 16 weeks if the patient has not lost at least 5% of their initial body weight.
March 2018	December 2017 (TA 495)	Palbociclib with an aromatase inhibitor (selective, small-molecule inhibitor of cyclindependent kinases 4 and 6)	For previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
March 2018	December 2017 (TA 496)	Ribociclib with an aromatase inhibitor	For previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
March 2018	January 2018 (TA 497)	Golimumab (Cytokine modulator)	For treating non-radiographic axial spondyloarthritis
March 2018	January 2018 (TA 498)	Lenvatinib with everolimus	For previously treated advanced renal cell carcinoma
March 2018	January 2018 (TA 499)	Glecaprevir–pibrentasvir (Maviret)	For treating chronic hepatitis C (genotypes 1-6)
March 2018	January 2018 (TA 500)	Ceritinib (tyrosine kinase inhibitor)	For untreated ALK-positive non-small-cell lung cancer

March 2018	January 2018 (TA 501)	Intrabeam radiotherapy system (mobile irradiation System)	For adjuvant treatment of early breast cancer
March 2018	January 2018 (TA 502)	Ibrutinib (tyrosine kinase inhibitor)	For treating relapsed or refractory mantle cell lymphoma
March 2018	January 2018 (TA 503)	Fulvestrant (estrogen receptor antagonists)	For untreated locally advanced or metastatic oestrogenreceptor positive breast cancer
March 2018	February 2018 (TA 504)	Pirfenidone (Pyridones)	For treating idiopathic pulmonary fibrosis
March 2018	February 2018 (TA 505)	Ixazomib (proteasome inhibitor) with lenalidomide and dexamethasone	For treating relapsed or refractory multiple myeloma
March 2018	February 2018 (TA 506)	Lesinurad (oral selective inhibitor of the URAT1 and OAT4 uric acid (UA))	For treating chronic hyperuricaemia in people with gout (together with a xanthine oxidase inhibitor)
May 2018	February 2018 (TA 507)	Sofosbuvir–velpatasvir–voxilaprevir	For treating chronic hepatitis C
May 2018	March 2018 (TA 508)	Autologous chondrocyte implantation using chondrosphere	For treating symptomatic articular cartilage defects of the knee
May 2018	March 2018 (TA 509)	Pertuzumab with trastuzumab and docetaxel	For treating HER2-positive breast cancer

May 2018	March 2018 (TA 510)	Daratumumab monotherapy (humanised monoclonal antibody that targets the CD38 protein)	For treating relapsed and refractory multiple myeloma
May 2018	March 2018 (TA 511)	Brodalumab (recombinant human monoclonal antibody)	For treating moderate to severe plaque psoriasis
May 2018	March 2018 (TA 512)	Tivozanib (tyrosine kinase inhibitor)	For treating advanced renal cell carcinoma
May 2018	March 2018 (TA 513)	Obinutuzumab (anti-lymphocyte monoclonal antibody)	For untreated advanced follicular lymphoma
May 2018	March 2018 (TA 514)	Regorafenib (inhibitor of several protein kinases)	For previously treated advanced hepatocellular carcinoma
May 2018	March 2018 (TA 515)	Eribulin (non-taxane microtubule dynamics inhibitor)	For treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
May 2018	March 2018 (TA 516)	Cabozantinib (inhibitor of several protein kinases)	For treating medullary thyroid cancer
May 2018	April 2018 (TA 517)	Avelumab (monoclonal antibody)	For treating metastatic Merkel cell carcinoma

May 2018	April 2018 (TA 518)	Tocilizumab (recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody)	For treating giant cell arteritis
July 2018	April 2018 (TA 519)	Pembrolizumab (Keytruda)	For the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy
July 2018	May 2018 (TA 520)	Atezolizumab (Tecentriq)	For treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumour)
July 2018	June 2018 (TA 521)	Guselkumab	For treating plaque psoriasis in adults
July 2018	June 2018 (TA 522)	Pembrolizumab	For untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable
July 2018	June 2018 (TA 523)	Midostaurin	For treating newly diagnosed acute FLT3-mutation-positive myeloid leukaemia with standard daunorubicin and cytarabine as induction therapy, with high-dose cytarabine as consolidation therapy, and alone after complete response as maintenance therapy
July 2018	June 2018 (TA 524)	Brentuximab vedotin	For treating CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease
July 2018	June 2018 (TA 525)	Atezolizumab	For treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy
July 2018	June 2018 (TA 526)	Arsenic trioxide	For inducing remission and consolidation in acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults

September 2018	June 2018 (TA527)	Beta-interferons and glatiramer acetate	Evidence-based recommendations for treating multiple sclerosis in adults.
September 2018	July 2018 (TA528)	Niraparib	For treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults
September 2018	July 2018 (TA529)	Crizotinib	For treating ROS1-positive advanced non-small-cell lung cancer
September 2018	July 2018 (TA 530)	Nivolumab	For treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
September 2018	July 2018 (TA 531)	Pembrolizumab	For untreated PD-L1-positive metastatic non-small-cell lung cancer
September 2018	July 2018 (TA 532)	Cenegermin	For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults
September 2018	July 2018 (TA 533)	Ocrelizumab	For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features
September 2018	August 2018 (TA534)	Dupilumab	For the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy
September 2018	August 2018 (TA 535)	Lenvatinib and sorafenib	For treating progressive, locally advanced or metastatic differentiated thyroid cancer
September 2018	August 2018 (TA 536)	Alectinib	For untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults
September 2018	August 2018 (TA 537)	Ixekizumab	For treating active psoriatic arthritis in adults
September 2018	August 2018 (TA 538)	Dinutuximab beta	For treating high-risk neuroblastoma
	August 2018 (TA 539)	Lutetium (177Lu) oxodotreotide	For 'unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in

			adults
November 2018	September 2018 (TA 540)	Pembrolizumab	For treating relapsed or refractory classical Hodgkin lymphoma
November 2018	September 2018 (TA 541)	Inotuzumab ozogamicin	For treating relapsed or refractory B-cell acute lymphoblastic leukaemia
November 2018	October 2018 (TA 542)	Cabozantinib	For untreated advanced renal cell carcinoma
November 2018	October 2018 (TA 543)	Tofacitinib	For treating active psoriatic arthritis after inadequate response to DMARDs
November 2018	October 2018 (TA 544)	Dabrafenib with trametinib	For adjuvant treatment of resected BRAF V600 mutation-positive melanoma
January 2019	November 2018 (TA545)	Gemtuzumab ozogamicin (monoclonal antibody)	For untreated acute myeloid leukaemia
January 2019	November 2018 (TA 546)	Padeliporfin	For untreated localised prostate cancer
January 2019	November 2018 (TA 547)	Tofacitinib	For moderately to severely active ulcerative colitis
January 2019	December 2018 (TA 550)	Vandetanib	For treating medullary thyroid cancer

January 2019	December 2018 (TA 551)	Lenvatinib	For untreated advanced hepatocellular carcinoma
January 2019	December 2018 (TA 552)	Liposomal cytarabine-daunorubicin	For untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults
January 2019	December 2018 (TA 553)	Pembrolizumab	For adjuvant treatment of resected melanoma with high risk of recurrence
January 2019	December 2018 (TA554)	Tisagenlecleucel	For treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
March 2019	Jan 2019 (TA555)	Regorafenib	Previously treated advanced hepatocellular carcinoma
March 2019	Jan 2019 (TA 556)	Darvadstrocel	Complex perianal fistulas in Crohn's disease
March 2019	Jan 2019 (TA 557)	Pembrolizumab (with pemetrexed and platinum chemotherapy)	untreated, metastatic, non-squamous non-small-cell lung cancer
March 2019	Jan 2019 (TA 558)	Nivolumab	Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
March 2019	Jan 2019 (TA 559)	Axicabtagene ciloleucel	Option for treating relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in

			the managed access agreement are followed.
March 2019	Jan 2019 (TA 561)	Venetoclax with rituxumab	Chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy
March 2019	Jan 2019 (TA562)	Encorafenib with binimetinib	Unresectable or metastatic BRAF V600 mutation-positive melanoma
March 2019	Jan 2019 (TA563)	Abemaciclib with aromatase inhibitor	for untreated, hormone receptor-positive, HER2- negative locally advanced or metastatic breast cancer
May 2019	March 2019 (TA 565)	Benralizumab (Fasenra)	Add on therapy for treating severe eosinophilic asthma in adults.
May 2019	March 2019 (TA 566)	Cochlear Implant	For children and adults with severe to profound deafness
May 2019	March 2019 (TA 567)	Tisagenlecleucel Immunocellular CAR T-cell therapy. Contains the patient's own T cells (a type of white blood cell) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR)	Treatment of relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (adults)
May 2019	March 2019 (TA 569)	Pertuzumab (with trastuzumab)	Adjuvant treatment of HER2-positive early stage breast cancer

May 2019	March 2019 (TA 571)	Brigatinib	Anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer previously treated with crizotinib (Adults)
May 2019	March 2019 (TA572)	Ertugliflozin	Monotherapy or with metformin for treating type 2 diabetes in adults
May 2019	April (TA573)	Daratumumab with (bortezomib and dexamethasone)	Previously treated multiple myeloma in adults.
May 2019	April (TA574)	certolizumab pegol (Cimzia)	for treating moderate to severe plaque psoriasis in adults.
May 2019	April (TA575)	Tildrakizumab (Ilumetri)	moderate to severe plaque psoriasis in adults
May 2019	April (TA577)	Brentuximab vedotin (Adcetris)	CD30-positive cutaneous T-cell lymphoma in adults
July 2019	MAY 2019 (TA 578)	Durvalumab (Imfinz)	Monotherapy for the treatment of locally advanced, unresectable non-small-cell lung cancer in adults whose tumours express PD-L1 on $\geq 1\%$ of tumour cells and whose disease has not progressed following platinum-based chemoradiation
July 2019	MAY 2019 (TA 579)	Abemaciclib (Verzenios)	Treatment of hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative locally advanced or metastatic breast cancer in adults who have had endocrine therapy.

July 2019	MAY 2019 (TA 581)	Nivolumab (with Ipilimumab)	For untreated advanced renal carcinoma
July 2019	JUNE (TA583)	Ertugliflozin (Steglatro) As monotherapy or with metformin and a dipeptidyl peptidase-4 inhibitor	Treatment of type 2 diabetes in adults
July 2019	JUNE (TA584)	Atezolizumab (Tecentriq, Roche) plus bevacizumab (Avastin, Roche), paclitaxel and carboplatin	Treatment of metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults: who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49% Or when targeted therapy for epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase (ALK)-positive NSCLC has failed
July 2019	JUNE (TA585)	Ocrelizumab	Treatment of early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults
July 2019	JUNE (TA586)	Lenalidomide With dexamethasone	Treatment of multiple myeloma after 1 treatment with bortezomib
July 2019	JUNE (TA587)	Lenalidomide plus dexamethasone	For previously untreated multiple myeloma in adults who are not eligible for a stem cell transpla
September 2019	JULY 2019 (TA 588)	Nusinersen (Spinraza)	Treatment of spinal muscular atrophy (SMA) in children and adults.

September 2019	JULY 2019 (TA 589)	Blinatumomab (Blincyto)	Treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.
September 2019	JULY 2019 (TA 590)	Fluocinolone acetonide intravitreal implant (Iluvien)	Treatment of recurrent non-infectious uveitis in adults
September 2019	JULY 2019 (TA 591)	Letermovir (Prevymis)	Treatment for preventing cytomegalovirus disease after a stem cell transplant.
September 2019	AUGUST 2019 (TA 592)	Cemiplimab (Libtayo)	For treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults.
September 2019	AUGUST 2019 (TA 593)	Ribociclib (Kisqali)	Treatment for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy. Recommended for use within the Cancer Drugs Fund
September 2019	AUGUST 2019 (TA 595)	Dacomitinib (Vizimpro)	For untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults. (1 st line treatment)
September 2019	AUGUST 2019 (TA 596)	Risankizumab (Skyrizi)	For treating moderate to severe plaque psoriasis in adults.
November 2019	AUGUST 2019 (TA 597)	Dapagliflozin (Forxiga)	Adjunct with Insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a body mass index (BMI) of at least 27 kg/m ² .

November 2019	AUGUST 2019 (TA 598)	Olaparib (Lynparza)	Treatment of BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults.
November 2019	SEPT 2019 (TA 599)	Sodium zirconium cyclosilicate (Lokelma)	Treatment of hyperkalaemia in adults.
November 2019	SEPT 2019 (TA 600)	Pembrolizumab (Keytruda) with carboplatin and paclitaxel	Treatment for adults with untreated metastatic squamous non-small-cell lung cancer.
November 2019	OCT 2019 (TA 604)	Xeomin (botulinum neurotoxin type A)	For treating chronic sialorrhoea caused by neurological conditions in adults
November 2019	OCT 2019 (TA 606)	Lanadelumab	For preventing recurrent attacks of hereditary angioedema
November 2019	OCT 2019 (TA 607)	Rivaroxaban	For preventing atherothrombotic events in people with coronary or peripheral artery disease

Last updated November 2019